View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsDMK Pharmaceuticals 将来の成長Future 基準チェック /06現在、 DMK Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長12.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Sep 10Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted an order for the extension of the exclusivity period DMK Pharmaceuticals Corporation on September 9, 2024. As per the order, the debtor’s exclusivity period to solicit votes on its plan has been extended by 30 days i.e. up to October 31, 2024.お知らせ • Aug 03Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals CorporationDMK Pharmaceuticals Corporation, along with its affiliates, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on August 2, 2024. As per the plan filed, administrative expense claims, fee claims, priority tax claims, U.S. Trustee fees, and priority non-tax claims of $979 shall be paid in full in cash. Allowed secured claims are of $0. Allowed unsecured claims of $25.34 million shall be recovered 3.4% i.e., $0.86 million pro rata share of distributions from liquidation trust assets as beneficiaries of the liquidation trust until they have received payment in full. Subordinated claims of $16.96 million shall not receive or retain any distribution under the plan. Equity interests will be extinguished on the effective date and shall not receive or retain any distribution under the plan. The plan shall be funded by the liquidation trust assets, other than the professional fees reserve. on the effective date, the debtors shall fund the professional fees reserve in full in cash.お知らせ • Jun 15First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted first order for the extension of the exclusivity periods for DMK Pharmaceuticals Corporation on June 14, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e., up to August 2, 2024, and October 1, 2024, respectively.お知らせ • May 09Motion for Asset Sale Approved for DMK Pharmaceuticals CorporationThe US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer.お知らせ • Mar 22Nasdaq to Delist Common Stock of DMK PharmaceuticalsNasdaq announced that it will delist the common stock of DMK Pharmaceuticals Corporation. DMK Pharmaceuticals’s securities were suspended on February 7, 2024, and have not traded on Nasdaq since that time.お知らせ • Feb 08DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI IndexDMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Indexお知らせ • Feb 07DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite IndexDMK Pharmaceuticals Corporation has been dropped from Nasdaq Composite Index.お知らせ • Jan 06DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024, at 09:00 Pacific Standard Time.お知らせ • Nov 29DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPIDMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.お知らせ • Nov 22Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite IndexAdamis Pharmaceuticals Corporation has been dropped from NASDAQ Composite Index.お知らせ • Oct 21DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn October 18, 2023, DMK Pharmaceuticals Corporation received a superseding notice from the Staff, indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company's non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq. At the hearing, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company's request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing.お知らせ • Oct 20+ 1 more updateDMK Pharmaceuticals Corporation Announces CFO ChangesDMK Pharmaceuticals Corporation announced a series of management changes to optimize its leadership structure. Seth Cohen has been appointed as Chief Financial Officer and John Dorbin will assume the position of General Counsel Corporate Secretary. Mr. Cohen will be succeeding the outgoing interim CFO and President and Chief Operating Officer, David Marguglio. These organizational changes will be effective immediately. The new team is tasked with operating a lean and effective organization committed to increasing the sales of DMK’s existing commercial products and advancing its clinical pipeline. Mr. Cohen has over thirty years of experience in business and finance. Since 2011, Mr. Cohen has been a principal at CFOX Consulting, LLC, an advisory firm that specializes in CFO and related services for public, private equity backed, and start-up businesses. From 2000 to 2011, Mr. Cohen served in various leadership roles of increasing responsibility at Newtek Business Services Inc. In 2007, he was appointed CFO and tasked with directing the corporate accounting and finance department as well as overseeing the company’s various subsidiaries. Prior to that, Mr. Cohen served as Director of the Mayor’s Office of Pensions and Public Finance for the City of New York where he managed the securitization of assets, oversaw multibillion-dollar debt issuances, and initiated and helped oversee pension policy. As a trustee for the City of New York’s five pension systems, Mr. Cohen oversaw $100 billion in assets. He developed his corporate and municipal finance skills at Lehman Brothers, Patricof & Co., and Dean Witter Reynolds Inc. Mr. Cohen holds an MBA from Columbia Business School and a B.A. from Yale University.お知らせ • Oct 18DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock MarketAs previously disclosed, on April 12, 2023, DMK Pharmaceuticals Corporation received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that the market value of the Company’s common stock closed below the minimum $35 million threshold required by Nasdaq Listing Rule 5550(b)(2) for the previous 30 consecutive trading days and, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until October 9, 2023, to regain compliance with the Rule. On October 11, 2023, the Company received notice from the Staff that the Company’s common stock was subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance with the Rule prior to the expiration of any extension that may be granted to the Company following the hearing.お知らせ • Oct 11DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price RequirementsOn October 4, 2023, DMK Pharmaceuticals Corporation received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the $1.00 minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. Based on the closing bid price of the Company’s common stock for at least 30 consecutive business days before receipt of the Notice, the Company no longer meets the minimum bid price requirement of the Rule. This notice has no immediate effect on the Company’s Nasdaq listing or the trading of its common stock. The Notice indicated that the Nasdaq Listing Rules provide the Company a compliance period of 180 calendar days from the date of the Notice, or until April 1, 2024, to regain compliance, pursuant to Listing Rule 5810(c)(3)(A). The Notice stated that if at any time during the compliance period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, the Staff will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. The Notice also stated that if the Company does not regain compliance within the initial compliance period, it may be eligible for an additional 180-day compliance period. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period. The Notice stated that if the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. The Notice also stated that if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that it will not be granted additional 180 days for compliance and will be subject to delisting at that time. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance that any such appeal would be successful. There are no assurances that the Company will be able to regain compliance with the Rule or will otherwise be in compliance with other Nasdaq listing requirements.お知らせ • Sep 02Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023.お知らせ • Aug 06Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,800,000 Price\Range: $1.35 Discount Per Security: $0.0945 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 1,130,000 Price\Range: $1.3499 Discount Per Security: $0.09449お知らせ • Jul 26+ 1 more updateAdamis Pharmaceuticals Corporation Announces Chief Financial Officer ChangesOn July 18, 2023, David C. Benedicto, the chief financial officer of Adamis Pharmaceuticals Corporation (Company), notified the company that he was tendering his resignation from the company effective July 21, 2023. The Company will commence a search for a new chief financial officer. In the interim, David J. Marguglio, the Company’s President and Chief Operating Officer, will assume the duties of chief financial officer of the Company on an interim basis until the company appoints a successor, and the board of directors of the Company has approved that appointment. Mr. Marguglio joined the Company as Vice President, Business Development and Investor Relations, and a director in April 2009, and was appointed as President and Chief Executive Officer of the Company in May 2022 and was Chief Executive Officer until the Company’s merger in May 2023 with DMK Pharmaceuticals Corporation. He has held positions with the Company of Senior Vice President of Corporate Development and, since March 2017, Senior Vice President and Chief Business Officer. Prior to Adamis, Mr. Marguglio held various positions with Citigroup Global Markets, Salomon Smith Barney and Merrill Lynch. Before entering the financial industry, he worked as a financial analyst and founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company. He received a degree in finance and business management from the Hankamer School of Business at Baylor University.お知らせ • May 26Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) entered into an Agreement to acquire DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on February 24, 2023. At the close of the merger, Eboo Versi, the current CEO of DMK, will assume the role of CEO and chairman of the combined company, David J. Marguglio, the current chief executive officer and President of Adamis, is expected to continue as President of the company and David C. Benedicto is expected to continue as the chief financial officer of the company. The transaction is subject to approval by the Adamis and DMK’s stockholders. The transaction was approved by the boards of directors of both companies and expected to close during the second quarter of 2023.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) completed the acquisition of DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on May 25, 2023. In connection with the merger, Ebrahim Versi assumed the role of Chief executive officer and Chairman of the Board and David J. Marguglio previously Chief Executive Officer of Adamis, will assume the role of President and Chief Operating Officer of the combined company. Ebrahim Versi and DMK board member Jannine Versi, have been appointed to the Board and join the pre-merger Adamis directors Howard C. Birndorf, Meera J. Desai, PhD, and Vickie Reed as the new Board of the combined company. Adamis Chairman, Richard C. Williams, and David J. Marguglio resigned their prior director roles in connection with the closing of the merger. Combined company will have commercial products and a library of development candidates, including two clinical stage programs.DPI-125, the lead development program, is a clinical stage therapeutic under investigation for the treatment of opioid use disorder.お知らせ • May 20+ 1 more updateAdamis Pharmaceuticals Corporation Contemplates Bankruptcy Adamis Pharmaceuticals Corporation is contemplating filing for bankruptcy, as of May 19, 2023. According to company press release, the managing director said that If we do not obtain required additional equity or debt funding in the near term, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations or satisfy out liabilities, we could be required to seek bankruptcy protection or other alternatives to attempt to resolve our obligations and liabilities that could result in our stockholders losing most or all their investment in us.お知らせ • May 09Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023Adamis Pharmaceuticals Corporation announced that they will report Q1, 2023 results at 1:00 PM, Pacific Standard Time on May 15, 2023Board Change • Mar 04Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 23Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: US$0.035 loss per share (up from US$0.10 loss in 3Q 2020). Revenue: US$760.0k (down 82% from 3Q 2020). Net loss: US$5.17m (loss narrowed 31% from 3Q 2020). Revenue missed analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 27% compared to a 19% growth forecast for the industry in the United Kingdom.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、DMK Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測LSE:0A4X - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20234-21-9-9N/A6/30/20235-24-13-13N/A3/31/20235-25-21-20N/A12/31/20225-26-27-26N/A9/30/20221-31-32-31N/A6/30/20221-32-34-33N/A3/31/20222-31-41-40N/A12/31/20212-35-39-38N/A9/30/20214-39-37-36N/A6/30/20214-43-33-33N/A3/31/20210-42-22-21N/A12/31/20203-36-21-21N/A9/30/20208-28-19-18N/A6/30/202013-25-18-17N/A3/31/202022-26-17-16N/A12/31/201922-28-23-20N/A9/30/201921-36-32-29N/A6/30/201919-38-37-33N/A3/31/201917-40-38-33N/A12/31/201815-39-36-33N/A9/30/201814-34-29-26N/A6/30/201813-32-23-21N/A3/31/201813-27-22-20N/A12/31/201713-26-17-15N/A9/30/201713-18-15-13N/A6/30/201711-19N/A-17N/A3/31/201710-20N/A-20N/A12/31/20166-21N/A-21N/A9/30/20164-24N/A-20N/A6/30/20162-19N/A-16N/A3/31/2016N/A-17N/A-12N/A12/31/2015N/A-14N/A-10N/A9/30/2015N/A-14N/A-11N/A6/30/2015N/A-13N/A-10N/A3/31/2015N/A-12N/A-10N/A12/31/2014N/A-11N/A-9N/A9/30/2014N/A-12N/A-9N/A6/30/2014N/A-10N/A-8N/A3/31/2014N/A-8N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0A4Xの予測収益成長が 貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 0A4Xの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 0A4Xの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 0A4Xの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 0A4Xの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0A4Xの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/11/20 19:08終値2024/10/08 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DMK Pharmaceuticals Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Andrew D'SilvaB. Riley Securities, Inc.Jason KolbertH.C. Wainwright & Co.Jason KolbertMaxim Group2 その他のアナリストを表示
お知らせ • Sep 10Second Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted an order for the extension of the exclusivity period DMK Pharmaceuticals Corporation on September 9, 2024. As per the order, the debtor’s exclusivity period to solicit votes on its plan has been extended by 30 days i.e. up to October 31, 2024.
お知らせ • Aug 03Joint Liquidation Plan and Disclosure Statement Filed by DMK Pharmaceuticals CorporationDMK Pharmaceuticals Corporation, along with its affiliates, filed a joint plan of liquidation with related disclosure statement in the US Bankruptcy Court on August 2, 2024. As per the plan filed, administrative expense claims, fee claims, priority tax claims, U.S. Trustee fees, and priority non-tax claims of $979 shall be paid in full in cash. Allowed secured claims are of $0. Allowed unsecured claims of $25.34 million shall be recovered 3.4% i.e., $0.86 million pro rata share of distributions from liquidation trust assets as beneficiaries of the liquidation trust until they have received payment in full. Subordinated claims of $16.96 million shall not receive or retain any distribution under the plan. Equity interests will be extinguished on the effective date and shall not receive or retain any distribution under the plan. The plan shall be funded by the liquidation trust assets, other than the professional fees reserve. on the effective date, the debtors shall fund the professional fees reserve in full in cash.
お知らせ • Jun 15First Motion for Exclusivity Period Extension Approved For DMK Pharmaceuticals CorporationThe US Bankruptcy Court granted first order for the extension of the exclusivity periods for DMK Pharmaceuticals Corporation on June 14, 2024. As per the order, the debtor’s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 60 days i.e., up to August 2, 2024, and October 1, 2024, respectively.
お知らせ • May 09Motion for Asset Sale Approved for DMK Pharmaceuticals CorporationThe US Bankruptcy Court gave an order approving the sale of substantially all the assets of DMK Pharmaceuticals Corporation on May 8, 2024. The debtor has been authorized to sell substantially all its assets to Zmi Management Inc for a purchase price of $3.17 million in cash. David R. Eastlake and Hans E. Biebl of Greenberg Traurig, LLP acted as legal advisors to the buyer.
お知らせ • Mar 22Nasdaq to Delist Common Stock of DMK PharmaceuticalsNasdaq announced that it will delist the common stock of DMK Pharmaceuticals Corporation. DMK Pharmaceuticals’s securities were suspended on February 7, 2024, and have not traded on Nasdaq since that time.
お知らせ • Feb 08DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI IndexDMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index
お知らせ • Feb 07DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite IndexDMK Pharmaceuticals Corporation has been dropped from Nasdaq Composite Index.
お知らせ • Jan 06DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024DMK Pharmaceuticals Corporation, Annual General Meeting, Jan 25, 2024, at 09:00 Pacific Standard Time.
お知らせ • Nov 29DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPIDMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI (epinephrine) Injection 0.3mg and SYMJEPI (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI and ZIMHI (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts. The Company is now actively seeking out-license opportunities for SYMJEPI in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.
お知らせ • Nov 22Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite IndexAdamis Pharmaceuticals Corporation has been dropped from NASDAQ Composite Index.
お知らせ • Oct 21DMK Pharmaceuticals Corporation Receives a Superseding Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn October 18, 2023, DMK Pharmaceuticals Corporation received a superseding notice from the Staff, indicating that the Prior Notice was issued in error. The Subsequent Notice indicated that because the Company was subject to a one-year Mandatory Panel Monitor as a result of a prior hearing before the Panel, the Company was not eligible for the automatic 180-day compliance grace period provided by Listing Rule 5810(c)(3)(A) and that the Company's non-compliance with the Bid Price Rule serves as an additional basis for delisting from Nasdaq. At the hearing, the Company will address its plan to regain compliance with both the Bid Price Rule and the MVLS Rule as well as its continued compliance with all other applicable criteria for continued listing on The Nasdaq Capital Market. There can be no assurance, however, that the Panel will grant the Company's request for continued listing or that the Company will evidence compliance with the listing rules prior to the expiration of any extension that may be granted by the Panel following the hearing.
お知らせ • Oct 20+ 1 more updateDMK Pharmaceuticals Corporation Announces CFO ChangesDMK Pharmaceuticals Corporation announced a series of management changes to optimize its leadership structure. Seth Cohen has been appointed as Chief Financial Officer and John Dorbin will assume the position of General Counsel Corporate Secretary. Mr. Cohen will be succeeding the outgoing interim CFO and President and Chief Operating Officer, David Marguglio. These organizational changes will be effective immediately. The new team is tasked with operating a lean and effective organization committed to increasing the sales of DMK’s existing commercial products and advancing its clinical pipeline. Mr. Cohen has over thirty years of experience in business and finance. Since 2011, Mr. Cohen has been a principal at CFOX Consulting, LLC, an advisory firm that specializes in CFO and related services for public, private equity backed, and start-up businesses. From 2000 to 2011, Mr. Cohen served in various leadership roles of increasing responsibility at Newtek Business Services Inc. In 2007, he was appointed CFO and tasked with directing the corporate accounting and finance department as well as overseeing the company’s various subsidiaries. Prior to that, Mr. Cohen served as Director of the Mayor’s Office of Pensions and Public Finance for the City of New York where he managed the securitization of assets, oversaw multibillion-dollar debt issuances, and initiated and helped oversee pension policy. As a trustee for the City of New York’s five pension systems, Mr. Cohen oversaw $100 billion in assets. He developed his corporate and municipal finance skills at Lehman Brothers, Patricof & Co., and Dean Witter Reynolds Inc. Mr. Cohen holds an MBA from Columbia Business School and a B.A. from Yale University.
お知らせ • Oct 18DMK Pharmaceuticals Corporation Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock MarketAs previously disclosed, on April 12, 2023, DMK Pharmaceuticals Corporation received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that the market value of the Company’s common stock closed below the minimum $35 million threshold required by Nasdaq Listing Rule 5550(b)(2) for the previous 30 consecutive trading days and, in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until October 9, 2023, to regain compliance with the Rule. On October 11, 2023, the Company received notice from the Staff that the Company’s common stock was subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq at least until the hearing is held and any extension the Panel may grant to the Company following the hearing expires. There can be no assurance, however, that the Panel will grant the Company’s request for continued listing or that the Company will regain compliance with the Rule prior to the expiration of any extension that may be granted to the Company following the hearing.
お知らせ • Oct 11DMK Pharmaceuticals Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price RequirementsOn October 4, 2023, DMK Pharmaceuticals Corporation received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the $1.00 minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. Based on the closing bid price of the Company’s common stock for at least 30 consecutive business days before receipt of the Notice, the Company no longer meets the minimum bid price requirement of the Rule. This notice has no immediate effect on the Company’s Nasdaq listing or the trading of its common stock. The Notice indicated that the Nasdaq Listing Rules provide the Company a compliance period of 180 calendar days from the date of the Notice, or until April 1, 2024, to regain compliance, pursuant to Listing Rule 5810(c)(3)(A). The Notice stated that if at any time during the compliance period the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, the Staff will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. The Notice also stated that if the Company does not regain compliance within the initial compliance period, it may be eligible for an additional 180-day compliance period. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period. The Notice stated that if the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. The Notice also stated that if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that it will not be granted additional 180 days for compliance and will be subject to delisting at that time. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance that any such appeal would be successful. There are no assurances that the Company will be able to regain compliance with the Rule or will otherwise be in compliance with other Nasdaq listing requirements.
お知らせ • Sep 02Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023Adamis Pharmaceuticals Corporation, Annual General Meeting, Nov 09, 2023.
お知らせ • Aug 06Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million.Adamis Pharmaceuticals Corporation has completed a Composite Units Offering in the amount of $8.005387 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 4,800,000 Price\Range: $1.35 Discount Per Security: $0.0945 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 1,130,000 Price\Range: $1.3499 Discount Per Security: $0.09449
お知らせ • Jul 26+ 1 more updateAdamis Pharmaceuticals Corporation Announces Chief Financial Officer ChangesOn July 18, 2023, David C. Benedicto, the chief financial officer of Adamis Pharmaceuticals Corporation (Company), notified the company that he was tendering his resignation from the company effective July 21, 2023. The Company will commence a search for a new chief financial officer. In the interim, David J. Marguglio, the Company’s President and Chief Operating Officer, will assume the duties of chief financial officer of the Company on an interim basis until the company appoints a successor, and the board of directors of the Company has approved that appointment. Mr. Marguglio joined the Company as Vice President, Business Development and Investor Relations, and a director in April 2009, and was appointed as President and Chief Executive Officer of the Company in May 2022 and was Chief Executive Officer until the Company’s merger in May 2023 with DMK Pharmaceuticals Corporation. He has held positions with the Company of Senior Vice President of Corporate Development and, since March 2017, Senior Vice President and Chief Business Officer. Prior to Adamis, Mr. Marguglio held various positions with Citigroup Global Markets, Salomon Smith Barney and Merrill Lynch. Before entering the financial industry, he worked as a financial analyst and founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company. He received a degree in finance and business management from the Hankamer School of Business at Baylor University.
お知らせ • May 26Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) acquired DMK Pharmaceuticals, Inc. from Windhover Ventures LLC.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) entered into an Agreement to acquire DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on February 24, 2023. At the close of the merger, Eboo Versi, the current CEO of DMK, will assume the role of CEO and chairman of the combined company, David J. Marguglio, the current chief executive officer and President of Adamis, is expected to continue as President of the company and David C. Benedicto is expected to continue as the chief financial officer of the company. The transaction is subject to approval by the Adamis and DMK’s stockholders. The transaction was approved by the boards of directors of both companies and expected to close during the second quarter of 2023.Adamis Pharmaceuticals Corporation (NasdaqCM:ADMP) completed the acquisition of DMK Pharmaceuticals, Inc. from Windhover Ventures LLC on May 25, 2023. In connection with the merger, Ebrahim Versi assumed the role of Chief executive officer and Chairman of the Board and David J. Marguglio previously Chief Executive Officer of Adamis, will assume the role of President and Chief Operating Officer of the combined company. Ebrahim Versi and DMK board member Jannine Versi, have been appointed to the Board and join the pre-merger Adamis directors Howard C. Birndorf, Meera J. Desai, PhD, and Vickie Reed as the new Board of the combined company. Adamis Chairman, Richard C. Williams, and David J. Marguglio resigned their prior director roles in connection with the closing of the merger. Combined company will have commercial products and a library of development candidates, including two clinical stage programs.DPI-125, the lead development program, is a clinical stage therapeutic under investigation for the treatment of opioid use disorder.
お知らせ • May 20+ 1 more updateAdamis Pharmaceuticals Corporation Contemplates Bankruptcy Adamis Pharmaceuticals Corporation is contemplating filing for bankruptcy, as of May 19, 2023. According to company press release, the managing director said that If we do not obtain required additional equity or debt funding in the near term, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations or satisfy out liabilities, we could be required to seek bankruptcy protection or other alternatives to attempt to resolve our obligations and liabilities that could result in our stockholders losing most or all their investment in us.
お知らせ • May 09Adamis Pharmaceuticals Corporation to Report Q1, 2023 Results on May 15, 2023Adamis Pharmaceuticals Corporation announced that they will report Q1, 2023 results at 1:00 PM, Pacific Standard Time on May 15, 2023
Board Change • Mar 04Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 23Third quarter 2021 earnings: EPS in line with expectations, revenues disappointThird quarter 2021 results: US$0.035 loss per share (up from US$0.10 loss in 3Q 2020). Revenue: US$760.0k (down 82% from 3Q 2020). Net loss: US$5.17m (loss narrowed 31% from 3Q 2020). Revenue missed analyst estimates by 9.4%. Over the next year, revenue is expected to shrink by 27% compared to a 19% growth forecast for the industry in the United Kingdom.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Howard Birndorf was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.